Objective  To systematically evaluate the quality of guidelines, consensus and statements related to cardiovascular diseases.

Methods  Multiple Chinese and English databases and official guideline platforms were searched, including CNKI, WanFang Data, Scopus, PubMed, National Institute for Health and Care Excellence (NICE) and American Heart Association (AHA) websites from January 2008 to July 2025. Two researchers independently assessed the methodological quality of guidelines, consensus and statements. The methodological rigor of guidelines, consensuses and statements were evaluated using the internationally recognized AGREE II scale, and the reporting normality of statements was evaluated based on the RIGHT list. To ensure the credibility of the evaluation results, the consistency of the scores among researchers was tested by calculating the intraclass correlation coefficient (ICC).

Results  A total of 21 guidelines, 11 consensus and 3 statements were included. According to the evaluation results of AGREE II, the included guidelines, consensus and statements performed best in the two domains of "scope and purpose" (96.89%) and "clarity of presentation" (95.91%), and the average standardization scores were all higher than 95%. The scores in the fields of "stakeholder involvement" (75.23%), "rigour of development" (77.06%) and "editorial independence" (71.29%) were at a medium level, while the score in the "applicability" field was relatively low (58.26%). Finally, 15 A-level and 20 B-level guidelines/consensuses/statements were selected. The average reporting rate of the RIGHT evaluation results was 58.95%, with the highest score in the "funding and conflict of interest statement and management" (90.00%) field. The scores in the three areas of "evidence" (56.66%), "recommendations" (34.00%) and "review and quality assurance" (58.33%) were relatively low. The scores in other areas, including "basic information" (67.50%), "background" (74.00%) and "other information" (66.67%), were at a medium level.

Conclusion  The methodological and reporting quality of guidelines, consensus and statements related to cardiovascular diseases need to be further improved. In the future, it is necessary to strictly follow international standards to formulate higher-quality guidelines, consensus and statements for cardiovascular diseases, and enhance the clinical applicability of recommendations.

1.杨乔西, 蔡军. 心血管疾病治疗药物研究进展[J]. 临床药物治疗杂志, 2025, 23(1): 40-48. [Yang QX, Cai J. Progress in cardiovascular drug research[J]. Clinical Medication Journal, 2025, 23(1): 40-48.] DOI: 10.3969/j.issn.1672-3384.2025.01.008.

2.国家心血管病中心. 中国心血管健康与疾病报告2023[M]. 北京: 中国协和医科大学出版社, 2024.

3.GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy(HALE), and population estimates in 204 countries and territories, 1950—2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1160-1203. DOI: 10.1016/S0140-6736(20)30977-6.

4.中国抗癌协会整合肿瘤心脏病学分会, 中华医学会超声医学分会, 中国超声心动图学会. 无创性影像学技术评估肿瘤治疗相关心血管毒性的临床应用指南(2023版)[J]. 中华医学杂志, 2023, 103(42): 3367-3383. [Chinese Anti-Cancer Association Society of Integrative Cardio-oncology, Ultrasound Branch of the Chinese Medical Association, Chinese Society of Echocardiography. Chinese guideline for the clinical application of noninvasive imaging technology in accessing cancer therapy-related cardiovascular toxicity (2023 edition)[J]. National Medical Journal of China, 2023, 103(42): 3367-3383.] DOI: 10.3760/cma.j.cn112137-20230908-00428.

5.吴洋, 李柏辰, 丁宇坤, 等. 《2023年AHA/ACC/ACCP/ASPC/NLA/PCNA慢性冠心病管理指南》解读[J]. 中国循证医学杂志, 2024, 24(9): 1094-1099. [Wu Y, Li BC, Ding YK, et al. Interpretation of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Chronic Coronary Artery Disease[J]. Chinese Journal of Evidence-Based Medicine, 2024, 24(9): 1094-1099.] DOI: 10.7507/1672-2531.202309014.

6.韦当, 王聪尧, 肖晓娟, 等. 指南研究与评价(AGREE Ⅱ)工具实例解读[J]. 中国循证儿科杂志, 2013, 8(4): 316-319. [Wei D, Wang CY, Xiao XJ, et al. Case study on the application of AGREE II tool for guideline research and evaluation[J]. Chinese Journal of Evidence-Based Pediatrics, 2013, 8(4): 316-319.] DOI: 10.3969/j.issn.1673-5501.2013.04.017.

7.曹晓, 杨秋玉, 赖鸿皓, 等. 中国营养指南和专家共识质量评价——基于AGREE Ⅱ和RIGHT工具[J]. 现代预防医学, 2021, 48(16): 2918-2923. [Cao X, Yang QY, Lai HH, et al. China nutrition guide and expert consensus quality assessment-based on AGREE Ⅱ and RIGHT tools[J]. Modern Preventive Medicine, 2021, 48(16): 2918-2923.] DOI: 10.20043/j.cnki.mpm.2021.16.009.

8.贺兰芝, 周欣, 周鹏翔, 等. 多发性硬化指南和共识的方法学和报告质量评价[J]. 医学新知, 2025, 35(3): 328-338. [He LZ, Zhou X, Zhou PX, et al. Methodology and report quality evaluation of multiple sclerosis guidelines and consensus[J]. Yixue Xinzhi Zazhi, 2025, 35(3): 328-338.] DOI: 10.12173/j.issn.1004-5511.202410156.

9.钟优, 顿耀山, 魏文哲, 等. 心血管运动医学指南[J]. 中国循环杂志, 2024, 39(10): 937-955. [Zhong Y, Dun YS, Wei WZ, et  al. Cardiovascular medicine of sports and exercise guidelines[J]. Chinese Circulation Journal, 2024, 39(10): 937-955.] DOI: 10.3969/j.issn.1000-3614.2024.10.001.

10.中国药师协会, 海南博鳌县域医疗发展研究中心. 县域高血压合理用药与综合管理指南[J]. 中国合理用药探索, 2024, 21(8): 1-32. [Chinese Pharmacists Association, Hainan Boao County Health Development Research Center. Guideline for rational drug use and comprehensive management of hypertension in county[J]. China Journal of Rational Drug Use, 2024, 21(08): 1-32.] DOI: 10.3969/j.issn.2096-3327.2024.08.001.

11.中国高血压防治指南修订委员会, 高血压联盟(中国), 中国医疗保健国际交流促进会高血压病学分会, 等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志, 2024, 32(7): 603-700. [National Center for Cardiovascular Diseases Revision Committee, Hypertension League of China, Chinese Hypertension Association of the CPAM, et al. Chinese Clinical Practice Guideline for Hypertension (2024 Revision)[J]. Chinese Journal of Hypertension, 2024, 32(7): 603-700.] DOI: 10.16439/j.issn.1673-7245.2024.07.002.

12.中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3): 235-275. [Chinese Society of Cardiology, Cardiovascular Physician Branch of CMDA, Heart Failure Committee of CMDA, et al. Chinese guidelines for the diagnosis and management of heart failure 2024[J]. Chinese Journal of Cardiology, 2024, 52(3): 235-275.] DOI: 10.3760/cma.j.cn112148-20231101-00405.

13.中华人民共和国国家卫生健康委员会医政司. 肥胖症中国诊疗指南(2024年版)[J]. 协和医学杂志, 2025, 16(1): 90-108. [Department of Medical Administration, National Health Commission of the People's Republic of China. Chinese guidelines for the clinical management of obesity (2024 edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 16(1): 90-108.] DOI: 10.12290/xhyxzz.2024-0918.

14.上海市康复医学会肌肉骨骼中西医结合康复专业委员会《心脏疾病中西医结合康复指南》编写组, 上海中医药大学附属龙华医院康复医学科. 心脏疾病中西医结合康复指南[J]. 上海医药, 2024, 45(17): 15-28. [The Drafting Group of the "Guidelines for Integrated Traditional Chinese and Western Medicine Rehabilitation of Heart Diseases" by the Muscle and Skeleton Integrated Traditional Chinese and Western Medicine Rehabilitation Professional Committee of the Shanghai Rehabilitation Medicine Association, Rehabilitation Medicine Department of Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine. Guidelines for integrated traditional Chinese and Western medicine rehabilitation of heart diseases[J]. Shanghai Medical & Pharmaceutical Journal, 2024, 45(17): 15-28.] DOI: 10.3969/j.issn.1006-1533.2024.17.004.

15.国家老年医学中心, 中华医学会老年医学分会, 中国老年保健协会糖尿病专业委员会. 中国老年糖尿病诊疗指南(2024版)[J]. 协和医学杂志, 2024, 15(4): 771-800. [National Center of Gerontology, Chinese Society of Geriatrics, Diabetes Professional Committee of Chinese Aging Well Association. Guideline for the management of diabetes mellitus in the elderly in China (2024 edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 771-800.] DOI: 10.12290/xhyxzz.2024-0347.

16.中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(基层版2024年)[J]. 中国全科医学, 2024, 27(20): 2429-2436. [Joint Committee on the Chinese Guidelines for Lipid Management. Chinese guideline for lipid management (primary care version 2024)[J]. Chinese General Practice, 2024, 27(20): 2429-2436.] DOI: 10.12114/j.issn.1007-9572.2024.0005.

17.国家心血管病中心, 国家心血管病专家委员会心力衰竭专业委员会, 中国医师协会心力衰竭专业委员会, 等. 国家心力衰竭指南2023(精简版)[J]. 中国循环杂志, 2023, 38(12): 1207-1238. [National Center for Cardiovascular Diseases, China National Heart Failure Society, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Heart Failure and Cardiomyopathy, Editorial Board of Chinese Circulation Journal. National heart failure guideline 2023 (simplified version)[J]. Chinese Circulation Journal, 2023, 38(12): 1207-1238.] DOI: 10.3969/j.issn.1000-3614.2023.12.001.

18.中华医学会罕见病分会, 中国医师协会心血管内科医师分会心血管精准医学与罕见病学组. 成人心肌病无创影像技术临床诊断指南(2024版)[J]. 中华医学杂志, 2024, 104(44): 4038-4056. [Chinese Society of Rare Diseases, Working Group on Cardiovascular Precision Medicine and Rare Diseases, Cardiology Branch, Chinese Medical Doctor Association. Clinical guideline for non-invasive imaging techniques in diagnosing adult cardiomyopathies (2024 edition)[J]. National Medical Journal of China, 2024, 104(44): 4038-4056.] DOI: 10.3760/cma.j.cn112137-20240902-02027.

19.中华预防医学会, 中华预防医学会心脏病预防与控制专业委员会, 中华医学会糖尿病学分会, 等. 中国健康生活方式预防心血管代谢疾病指南[J]. 中国循环杂志, 2020, 35(3): 209-230. [Chinese Preventive Medicine Association, Branch of Heart Disease Prevention and Control, Chinese Preventive Medicine Association, Chinese Diabetes Society, et al. Chinese guideline on healthy lifestyle to prevent cardiometabolic diseases[J]. Chinese Circulation Journal, 2020, 35(3): 209-230.] DOI: 10.3969/j.issn.1000-3614.2020.03.001.

20.National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification[EB/OL]. (2023-12-14). https://www.nice.org.uk/guidance/ng238

21.National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management[EB/OL]. (2023-11-21). https://www.nice.org.uk/guidance/ng136

22.National Institute for Health and Care Excellence (NICE). Cardiovascular disease: identifying and supporting people most at risk of dying early[EB/OL]. (2008-09-24). https://www.nice.org.uk/guidance/ph15

23.National Institute for Health and Care Excellence (NICE). Stable angina: management [EB/OL]. (2016-08-25). https://www.nice.org.uk/guidance/cg126

24.National Institute for Health and Care Excellence (NICE). Chronic heart failure in adults: diagnosis and management[EB/OL]. (2025-09-03). https://www.nice.org.uk/guidance/ng106

25.Writing Committee Members, Thompson A, Fleischmann KE, et al. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2024, 84(19): 1869-1969. DOI: 10.1016/j.jacc.2024.06.013.

26.Royo-Bordonada MA, Lobos Bejarano JM, Villar Alvarez F, et  al. Statement of the Spanish Interdisciplinary Cardiovascular Prevention Committee (CEIPC for its Spanish acronym) on the 2012 European Cardiovascular Prevention Guidelines[J]. Neurologia, 2016, 31(3): 195-207. DOI: 10.1016/j.nrl.2013.04.011.

27.Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation, 2019, 140(11): e596-e646. DOI: 10.1161/CIR.0000000000000678.

28.Bushnell C, Kernan WN, Sharrief AZ, et al. 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association[J]. Stroke, 2024, 55(5): e344-e424. DOI: 10.1161/STR.0000000000000475.

29.Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2023, 148(9): e9-e119. DOI: 10.1161/CIR.0000000000001168.

30.中国医师协会中西医结合医师分会. 活心丸(浓缩丸)临床应用专家共识[J]. 中国中西医结合杂志, 2025, 45(2): 140-145. [Integrated Traditional and Western Medicine Physician Branch, Chinese Medical Doctor Association, Chen KJ, Wu ZG. Experts consensus on clinical application of Huoxin pills (concentrated pills)[J]. Chinese Journal of Integrated Traditional and Western Medicine, 2025, 45(2): 140-145.] DOI: 10.7661/j.cjim.20241209.186.

31.国家卫生健康委员会能力建设和继续教育中心, 孙艺红, 陈康, 等. 糖尿病患者合并心血管疾病诊治专家共识[J]. 中华内科杂志, 2021, 60(5): 421-437. [National Health Commission Capacity Building and Continuing Education Center, Sun YH, Chen K, et al. Expert consensus on the management of diabetic patients with cardiovascular diseases[J]. Chinese Journal of Internal Medicine, 2021, 60(5): 421-437.] DOI: 10.3760/cma.j.cn112138-20201208-00999.

32.董安琴, 贾杰, 陈欣, 等. 老年冠心病全周期康复中国专家共识[J]. 康复学报, 2024, 34(5): 426-437. [Dong  AQ, Jia J, Chen  X, et al. Chinese expert consensus on full-cycle rehabilitation of coronary heart disease in the elderly[J]. Rehabilitation Medicine, 2024, 34(5): 426-437. DOI: 10.3724/SP.J.1329.2024.05002.

33.中国老年医学学会心电与心功能分会, 中国心力衰竭芪苈强心研究协作组, 苏州工业园区东方华夏心血管健康研究院, 等. 慢性心力衰竭芪苈强心临床应用的专家共识[J]. 临床心血管病杂志, 2024, 40(12): 947-954. [Electrocardiology and Cardiac Function Branch of Chinese Geriatric Society, China Heart Failure Qili Qiangxin Collaborative Research Group, Suzhou Industrial Park Dongfang Huaxia Cardiovascular Health Institute, et al. Expert consensus on the clinical application of Qiliqiangxin for chronic heart failure[J]. Journal of Clinical Cardiology, 2024, 40(12): 947-954.] DOI: 10.13201/j.issn.1001-1439.2024.12.001.

34.朱为模, 李校堃, 付小兵, 等. 温泉结合运动疗法在疾病治疗和康复中的应用: 中国专家共识(2024)[J]. 体育科研, 2024, 45(6): 1-22. [Zhu WB, Li XK, Fu XB, et al. The clinical application of thermal therapy combined with exercise: Chinese expert consensus[J]. Sports Science Research, 2024, 45(6): 1-22.] DOI: 10.12064/ssr.2024100701.

35.中国抗癌协会整合肿瘤心脏病学分会, 《肿瘤相关高血压整合管理中国专家共识》专家组. 肿瘤相关高血压整合管理中国专家共识(2024年版)[J]. 中国肿瘤临床, 2024, 51(19): 993-1002. [Society of Integrative Cardio-Oncology, China Anti-Cancer Association, Expert Panel on Chinese Expert Consensus on Integrated Management of Cancer-Related Hypertension. Chinese expert consensus on integrated management of cancer-related hypertension (2024 version)[J]. Chinese Journal of Clinical Oncology, 2024, 51(19): 993-1002.] DOI: 10.12354/j.issn.1000-8179.2024.20241244.

36.中国医师协会内分泌代谢科医师分会, 国家心血管病专家委员会心血管代谢医学专业委员会. 糖尿病患者血脂管理中国专家共识(2024版)[J]. 中华糖尿病杂志, 2024, 16(4): 383-403. [Endocrinology and Metabolism Physician Branch of the Chinese Medical Doctor Association, National Society of Cardiometabolic Medicine. Expert consensus on the lipid management of diabetic patients (2024 edition)[J]. Chinese Journal of Diabetes, 2024, 16(4): 383-403.] DOI: 10.3760/cma.j.cn115791-20240301-00090.

37.中国医师协会心血管内科医师分会, 《中华内科杂志》编辑委员会. 心血管疾病一级预防中国专家共识[J]. 中华内科杂志, 2010, 49(2): 174-185. [Cardiovascular Physicians Branch of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Internal Medicine. Expert Consensus on Primary Prevention of Cardiovascular Disease in China[J]. Chinese Journal of Internal Medicine, 2010, 49(2): 174-185.] DOI: 10.3760/cma.j.issn.0578-1426.2010.02.031.

38.中国心血管疾病患者居家康复专家共识编写组. 中国心血管疾病患者居家康复专家共识[J]. 中国循环杂志, 2022, 37(2): 108-121. [Experts Consensus Group on Home-based Cardiac Rehabilitation in China. Experts consensus on home-based cardiac rehabilitation in China[J]. Chinese Circulation Journal, 2022, 37(2): 108-121.] DOI: 10.3969/j.issn.1000-3614.2022.02.002.

39.杭州市药事管理质控中心药品评价专家组, 浙江大学医学院附属杭州市第一人民医院. 心血管慢病药品临床综合评价杭州专家共识[J]. 中国药房, 2022, 33(9): 1025-1030. [Drug Evaluation Expert Group of Hangzhou Pharmaceutical Management Quality Control Center, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine. Hangzhou expert consensus on comprehensive clinical evaluation of drugs for chronic cardiovascular diseases[J]. China Pharmacy, 2022, 33(9): 1025-1030.] DOI: 10.6039/j.issn.1001-0408.2022.09.01.

40.Caldeira D, Franco F, Bravo Baptista S, et al. Air pollution and cardiovascular diseases: a position paper[J]. Rev Port Cardiol, 2022, 41(8): 709-717. DOI: 10.1016/j.repc.2022.05.006.

41.Rich MW, Chyun DA, Skolnick AH, et al. Knowledge gaps in cardiovascular care of the older adult population: a scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society[J]. J Am Coll Cardiol, 2016, 67(20): 2419-2440. DOI: 10.1016/j.jacc.2016.03.004.

42.Writing Committee, Birtcher KK, Allen LA, et al. 2022 ACC expert consensus decision pathway for integrating atherosclerotic cardiovascular disease and multimorbidity treatment: a framework for pragmatic, patient-centered care: a report of the American College of Cardiology Solution Set Oversight Committee[J].  J Am Coll Cardiol, 2023, 81(3): 292-317. DOI: 10.1016/j.jacc.2022.08.754.

43.Brauer M, Casadei B, Harrington RA, et al. Taking a stand against air pollution-the impact on cardiovascular disease: a joint opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology[J]. Circulation, 2021, 143(14): e800-e804. DOI: 10.1161/CIRCULATIONAHA.120.052666.

44.Zhou Q, Xing D, Li Q, et al. An extension of the RIGHT statement for introductions and interpretations of clinical practice guidelines: RIGHT for INT[J]. J Evid Based Med, 2022, 15(1): 55-63. DOI: 10.1111/jebm.12466.

45.Chen Y, Yang K, Marušic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement[J]. Ann Intern Med, 2017, 166(2): 128-132. DOI: 10.7326/M16-1565.